On Monday, August 16, Pfizer and BioNTech stated that they have submitted early-stage clinical trial data to the Food and Drug Administration as part of their U.S. application seeking authorization of a vaccine booster for the coronavirus for everyone 16 and older.
According to reports, in the phase one trial, a booster dose of the vaccine generated “significantly higher neutralizing antibodies” against the original COVID-19 strain as well as the beta and delta variants. Moreover, participants in the trial received a third shot of the two-dose vaccine about eight to nine months after receiving their second shot.
In addition, the companies informed that late-stage trial results evaluating the third dose are expected shortly and will also be submitted to the FDA and other regulatory authorities worldwide.
On the other hand, according to the research conducted by the University College London (UCL), the coronavirus antibody levels reportedly start to witness a decline as early as six weeks after complete vaccination with Pfizer and AstraZeneca jabs. Moreover, these can reduce by more than half over 10 weeks. Therefore, the need for booster doses may be pertinent in the future.
Meanwhile, the research published in The Lancet is based on data from over 600 people. The study further informs that the antibody levels are substantially higher following two doses of the Pfizer or AstraZeneca vaccine, manufactured in India as Covishield by Serum Institute of India (SII). Moreover, the antibodies are also much higher in those who have received both jabs after becoming infected with COVID-19.
Share
Tweet
